Table 1 Patient demographics and ovarian cancer disease characteristics (N = 39)
Age | Â | Baseline Platinum Status | n (%) |
   Median | 54.5 |    Platinum Refractory or Primary Resistant | 15 (38.5) |
   Range | 34.8-75.4 |    Secondary Platinum Resistant | 24 (61.5) |
Cancer Diagnosis | n (%) | Bulky Disease | Â |
   Ovary | 37 (94.9) |    Present | 11 (28.2) |
   Peritoneal | 1 (2.6) |    Absent | 27 (69.2) |
   Fallopian Tube | 1 (2.6) |    Unknown | 1 (2.6) |
ECOG Performance Status | Â | Ascites | Â |
   0 | 32 (82.1) |    Present | 7 (17.9) |
   1 | 5 (12.8) |    Absent | 32 (82.1) |
   2 | 1 (2.6) | Number of prior therapies |  |
   NA | 1 (2.6) |    Median (range) | 4.0 (2.0-10.0) |
FIGO Stage at Initial Diagnosis | Â | Number of prior cancer surgery | n (%) |
   IA | 1 (2.6) |    1 | 25 (64.1) |
   IC | 1 (2.6) |    2 | 13 (33.3) |
   IIC | 3 (7.7) |    3 | 1 (2.6) |
   III | 3 (7.7) | Number of prior radiation therapy |  |
   IIIA | 1 (2.6) |    0 | 35 (89.7) |
   IIIB | 2 (5.1) |    1 | 3 (7.7) |
   IIIC | 15 (38.5) |    2 | 1 (2.6) |
   IV | 4 (10.3) | Number of platinum-containing regimens |  |
   Unknown | 9 (23.1) |    1 | 14 (35.9) |
Race/Ethnicity |  |    2 | 17 (43.6) |
   Caucasian | 34 (87.2) |    3 | 5 (12.8) |
   Black | 2 (5.1) |    4 | 2 (5.1) |
   Asian | 2 (5.1) |    5 | 1 (2.6) |
   Hispanic | 1 (2.6) | Number of prior chemotherapy regimens (counting all prior platinum-containing regimens as one) |  |
   Other | 0 (0.0) |  |  |
|  |  |    1 | 16 (41.0) |
Histologic Subtype* |  |    2 | 11 (28.2) |
   Serous papillary | 30 (76.9) |    3 | 4 (10.3) |
   Mucinous | 0 (0.0) |    4 | 3 (7.7) |
   Poorly Differentiated | 2 (5.1) |    5 | 4 (10.3) |
   Endometrioid | 3 (7.7) |    6 | 1 (2.6) |
   Clear Cell | 7 (17.9) | Prior Chemotherapy* |  |
   Mixed | 4 (10.3) |    Platinum and Paclitaxel | 39 (100.0) |
Baseline CA125 (U/mL) |  |    Topotecan | 9 (23.1) |
   Median | 178.4 |    Docetaxel | 12 (30.8) |
   Range | 7.7--9321.1 |    Gemcitabine | 11 (28.2) |